Skip to main content
. 2024 Feb 1;18:306–321. doi: 10.1016/j.xjon.2024.01.014

Figure E1.

Figure E1

A, We assessed epithelial-mesenchymal transformation (EMT) makers (E-cadherin, vimentin, Zeb 1, and CYR-61) and identified primarily epithelial (H441, H358) and mesenchymal cell lines (H1299, SW1573). B, Angiotensin II type 1 receptor (AT1R) expression in all 5 lung cancer cell lines (magnification is 200 × ). C through E, AT1R expression in all 5 lung cancer cell lines treated with losartan alone or losartan combined with cisplatin. D, H441, ∗P = .001; H358, ∗P = .000; H1299, ∗P = .001; SW1573, ∗P = .003. E, H441, ∗P = .022, #P = .000; H358, ∗P = .000, #P = .013; H1299, ∗P = .043, #P = .029; SW1573, ∗P = .025, #P = .028. F, Zeb 1 expression with increasing losartan (H441, ∗P = .022; H358, ∗P = .014; H1299, ∗P = .001; SW1573, ∗P = .003; TC-1, ∗P = .001). G, Twist 1 expression with increasing losartan (H441, ∗P = .002; H358, ∗P = .024; H1299, ∗P = .020; SW1573, ∗P = .012; TC-1, ∗P = .001). H, Snail 1 expression with increasing losartan (H441, ∗P = .003; H358, ∗P = .001; H1299, ∗P = .001; SW1573, ∗P = .028; TC-1, ∗P = .024).